Original Source(s)
Related Content
Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs
by Ashik Anil Mathew, Arulkumaran Rithvik, Mahaboobkhan Rasool
July 9, 2026
Trial Exclusions May Skew RA Drug Comparisons
Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.
June 12, 2026
-
5 min